Crispr Therapeutics (NASDAQ:CRSP) Receives “Buy” Rating from Piper Jaffray Companies

Share on StockTwits

Crispr Therapeutics (NASDAQ:CRSP)‘s stock had its “buy” rating restated by equities research analysts at Piper Jaffray Companies in a research note issued on Tuesday, November 26th, TipRanks reports. They presently have a $104.00 price objective on the stock. Piper Jaffray Companies’ price target would suggest a potential upside of 44.24% from the company’s current price. Piper Jaffray Companies also issued estimates for Crispr Therapeutics’ Q1 2020 earnings at ($1.20) EPS, Q2 2020 earnings at ($1.30) EPS, Q3 2020 earnings at ($1.39) EPS, Q4 2020 earnings at ($1.49) EPS, FY2020 earnings at ($5.38) EPS, Q1 2021 earnings at ($1.65) EPS, Q2 2021 earnings at ($1.81) EPS, Q3 2021 earnings at ($1.88) EPS and FY2021 earnings at ($7.38) EPS.

Other equities analysts have also recently issued research reports about the stock. BidaskClub raised shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, November 15th. Canaccord Genuity raised their target price on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the company a “positive” rating in a research note on Wednesday, November 20th. Wells Fargo & Co reissued a “buy” rating on shares of Crispr Therapeutics in a research note on Tuesday, November 19th. Oppenheimer lifted their price objective on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research note on Monday, November 25th. Finally, Roth Capital lifted their price objective on shares of Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Crispr Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $69.54.

NASDAQ CRSP traded down $1.03 during trading hours on Tuesday, reaching $72.10. 1,328,629 shares of the company traded hands, compared to its average volume of 701,470. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $3.96 billion, a PE ratio of -20.96 and a beta of 3.30. The company has a 50 day moving average of $52.76 and a two-hundred day moving average of $46.89.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The company had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. On average, equities research analysts anticipate that Crispr Therapeutics will post 0.65 earnings per share for the current year.

In related news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the transaction, the director now owns 7,500 shares in the company, valued at approximately $412,500. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock worth $3,620,760 in the last quarter. Corporate insiders own 21.40% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of CRSP. Benjamin Edwards Inc. boosted its stake in Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after buying an additional 268 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Crispr Therapeutics by 13.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock valued at $118,000 after purchasing an additional 343 shares in the last quarter. Traynor Capital Management Inc. raised its position in shares of Crispr Therapeutics by 5.8% during the third quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock worth $280,000 after acquiring an additional 375 shares during the last quarter. Commonwealth Equity Services LLC raised its position in shares of Crispr Therapeutics by 2.2% during the third quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock worth $746,000 after acquiring an additional 386 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. increased its holdings in Crispr Therapeutics by 7.1% in the second quarter. D. E. Shaw & Co. Inc. now owns 7,019 shares of the company’s stock worth $331,000 after purchasing an additional 467 shares in the last quarter. Institutional investors and hedge funds own 49.81% of the company’s stock.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: How big is the FinTech market?

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.